about
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor.Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients.Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature.Non-Hodgkin's lymphoma of the renal pelvis.Developments in the systemic treatment of endometrial cancer.PO-39 - Primary thromboprophylaxis for ambulatory patients with advanced metastatic pancreatic cancer. A practical implementation of lessons from published experience.Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients.Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties.Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience.The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience.Clinicopathological features of ovarian carcinosarcomas: a single institution experience.Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.Carboplatin hypersensitivity reactions: a single institution experience.Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience.Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.Advances in managing and preventing thromboembolic disease in cancer patients.Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy.Prognostic assessment for patients with cancer and incidental pulmonary embolism.Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based ChemHigh-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trialPrognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution ExperienceBiweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinomaThe impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapyThe outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapyAdvanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcomeAnthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experienceAdjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterusGemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerUnsuspected visceral venous thrombosis, in patients with cancer of the gastrointestinal systemThe Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis
P50
Q30827244-77E994A0-611C-4F90-832A-DFB3C5DFAB89Q31088061-97722B09-FC46-41DE-B5EC-0D1D47AD43BCQ33633962-2DEFCEA9-F79B-48D6-B541-A0DB12486248Q34364930-7DDFCD21-7DD3-43BC-9A4C-30F387295873Q34785968-A8DB7740-DD33-4F46-8435-212B698F9E39Q36328434-91CFE5D6-2F5C-4A8D-A0CC-D9A56E47FEC9Q36461016-923BEF43-5160-400B-9B94-BE6808977E54Q37787589-342282AA-D85F-4985-8FDF-5F25B4F82C98Q39780952-4BB720BD-151D-4E6E-8FD5-45B0CF92EFEFQ40413780-05FEC263-82D3-4C17-9B3B-88FDBCE7CEA6Q40419958-491AF59F-E017-44DB-85B3-830F335BFF6DQ40429650-86CEB49C-3022-4C3F-B07A-CE46A9DD8240Q41710487-895694DD-31A7-4939-8503-D85C04E7EF5BQ43044764-A56A468E-AC7F-4FD2-AE39-39F90384E139Q43281087-D791C755-54F8-43B9-944C-2F09957E9AF2Q43660477-99B96EA6-905D-430A-AF79-9788DC3CC2E0Q44327702-FA51999C-77C3-476C-A612-D84F2F714BA6Q44639028-916AE7B0-B7D4-4E9E-A0B3-CC0ABE458C77Q44946944-88208A9E-5269-4597-A426-4355D9A5794EQ45181400-45D5F53E-BA3F-4DDB-8315-634D6464E305Q45236388-3149B286-9FB4-49A7-A02F-E4FD9120F7A3Q46436193-BE81BFC7-E004-4E9C-A8A1-8EBF41682E0EQ46487813-4ABFEAEC-A0C0-44C5-947B-665911A52EF9Q46825147-1399BB23-431D-4A1B-AE18-46740CBBE862Q47721677-F38BE199-34B9-40D7-87C0-F4C93DAD00B8Q48486439-C2DAAE90-4439-448F-AAA9-307BE51FE45FQ50014624-53109BCA-EE73-4045-9368-0626D221D178Q57904649-BBA51B5F-B2B4-419D-9C60-4C149C6F2773Q57904758-C3284345-944C-4991-8AE6-09FD58A6A6D8Q57904776-1DEBF178-F9A3-4C23-9A64-7E0C39C64EB0Q57904791-6CF61453-3B26-420A-941B-9843F16C4208Q57904826-A53AA426-5E14-4CBE-B4DC-B5A08861380CQ57904936-E94FA717-75B2-4863-809B-47273712FB53Q79911280-B68D4B85-8E95-4A3D-AF01-86C2E032EA7DQ80266842-FB718072-3384-44D2-8E28-630CD2C779D8Q82198615-8D7924C1-8AA8-4084-99C1-F3D5ED5A7259Q82597285-DA16E86E-7E38-49F7-8C65-E618293CB9C1Q84649607-B2060DF6-42BD-46B4-9618-E93A48285D07Q93234623-BEC66BD9-FB4D-4375-BDEE-BAC96C2A288B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
George Bozas
@ast
George Bozas
@en
George Bozas
@es
George Bozas
@nl
George Bozas
@sl
type
label
George Bozas
@ast
George Bozas
@en
George Bozas
@es
George Bozas
@nl
George Bozas
@sl
prefLabel
George Bozas
@ast
George Bozas
@en
George Bozas
@es
George Bozas
@nl
George Bozas
@sl
P106
P1153
11338959300
P21
P31
P496
0000-0003-1749-4855